The company has recently reported positive randomised Phase II sarcoma interim data for intravenous palifosfamide at the Annual Meeting of the Connective Tissue Oncology Society (CTOS) on November 6, 2009 and expects, following FDA review, to initiate a registration trial the first half of 2010.
Furthermore, the company has also been granted US Patent for darinaparsin, for the treatment of cancer. The company also expects to initiate a registration trial for darinaparsin in peripheral T-cell lymphoma following FDA review.
Additionally, Ziopharm has been granted Patent No 2326833 by the Canadian Intellectual Property office covering certain N-substituted indole-3-glyoxylamides, including indibulin, for use as an antitumor agent.
Jonathan Lewis, CEO of Ziopharm, said: “With this notice of allowance for palifosfamide, we now have established a US patent position for all three of our product candidates. With the additional issuances for darinaparsin and indidibulin, we continue to add to our patent estates, and will continue doing so for all three programs.”